𝔖 Bobbio Scriptorium

✦ LIBER ✦

Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*

✍ Scribed by Ridker, P. M

Book ID: 121755260
Publisher: Lippincott Williams and Wilkins
Year: 2003
Tongue: English
Weight: 427 KB
Volume: 108
Category: Article
ISSN: 0009-7322
DOI: 10.1161/01.CIR.0000100688.17280.E6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline Characteristics of Participants

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

✍ Paul M. Ridker; Francisco A.H. Fonseca; Jacques Genest; Antonio M. Gotto; John J 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Prevalence of Low Low-Density Lipoprotei

Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.: Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study

✍ Erin D. Michos; Roger S. Blumenthal 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 196 KB

Efficacy of Rosuvastatin Among Men and W

Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein: A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention–an Intervention Trial Evaluating Rosuvastatin) Trial

✍ Paul M. Ridker; Jean MacFadyen; Michael Cressman; Robert J. Glynn 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 502 KB

Further reduction of low-density lipopro

Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia

✍ Evan A. Stein; Leiv Ose; Kjetil Retterstøl; Serena Tonstad; Margo Schleman; Susa 📂 Article 📅 2007 🏛 Elsevier 🌐 English ⚖ 122 KB

Achievement of specified low-density lip

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)

✍ Jennifer G. Robinson; Christie M. Ballantyne; Willa Hsueh; Jeffrey Rosen; Jianxi 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 469 KB

The role of niacin in raising high-densi

The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH)

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 274 KB